Test Price
2,800 AED✅ Home Collection Available
CEBPA Germline Mutation Genetic Test for AML in UAE – 2,800 AED
Executive Summary & Core Metrics
- 99.9% Diagnostic Sensitivity – Next‑Generation Sequencing for CEBPA germline mutation detection.
- Turnaround Time: 3–4 Weeks
- Sample Type: Whole blood, extracted DNA, or dried blood spot (FTA card)
- Home Collection: VIP mobile phlebotomy 8 AM‑11 PM, temperature‑controlled cold chain.
- Post‑Test Guidance: Telephonic interpretation by DHA‑licensed geneticist.
- Insurance Billing: Direct verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The CEBPA germline NGS test identifies inherited mutations in the CEBPA gene that predispose to familial acute myeloid leukemia (AML). This comprehensive assay screens the entire coding region for all pathogenic variants using next‑generation sequencing, enabling risk assessment, early surveillance, and personalised family planning.
| Feature | Our NGS Test | Sanger Sequencing / Single‑Gene Assay |
|---|---|---|
| Diagnostic Sensitivity | 99.9% (full coding region, all variant types) | ~95% (limited to selected exons) |
| Methodology | Next‑Generation Sequencing (NGS) | Sanger sequencing or targeted PCR |
| Turn‑Around Time | 3‑4 Weeks | 4‑6 Weeks |
| Regulatory Compliance | DHA Accredited, ISO 9001:2015, UAE PDPL | Variable |
Physician Insight & Safety Protocols
“As a DHA‑licensed Consultant Medical Geneticist, I emphasize that a positive CEBPA germline result does not equate to a leukemia diagnosis; it reveals inherited susceptibility. All results must be interpreted alongside a full clinical history and family pedigree, and shared with your treating oncologist or haematologist for preventive strategies. Do not discontinue any prescribed medication without direct consultation.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA License 9294403
Pre‑Test Advisory & Genetic Counselling
- Genetic counselling is mandatory before testing. A certified genetic counsellor will review your family history, explain potential outcomes, and ensure informed consent. This step is mandated by UAE Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Provide a detailed clinical history and family pedigree if available.
- No fasting required. Continue regular medications unless otherwise directed.
- For whole blood, avoid samples that are clotted or haemolysed; inform us if you have had a blood transfusion in the past 2 weeks.
Safety Exclusions & Urgent Red Flags
- Exclusion Criteria: Patients who have received allogeneic hematopoietic stem cell transplant within the past 3 months (donor DNA interference). Active severe sepsis or haemodynamic instability at the time of collection.
- Genetic Counselling Mandatory: Per Federal Decree-Law No. 4 of 2016 on Medical Liability, minors require parental or guardian consent.
- Emergency Symptoms – Seek Immediate Medical Attention: If the patient develops new acute bleeding, sudden high fever >38.5°C, severe weakness, or petechiae, do not wait for test results – go to the nearest Emergency Department. This test is not for acute leukaemia management.
- Data Privacy: Your genomic data are protected under UAE PDPL (Federal Decree-Law No. 45 of 2021) and Federal Law No. 2 of 2019; shared only with authorised healthcare professionals.
Patient FAQ & Clinical Guidance
1. What does the CEBPA germline test detect?
Our NGS test detects inherited CEBPA mutations linked to familial AML with 99.9% diagnostic sensitivity. It identifies germline mutations in the entire CEBPA gene, which significantly increase the lifetime risk of developing acute myeloid leukemia. A positive result guides personalised surveillance and family screening.
2. Why is genetic counselling required before testing?
Genetic counselling ensures accurate pedigree analysis and informed consent before testing for inherited CEBPA mutations. A certified genetic counsellor will review your family history, explain potential outcomes, and support you in understanding the implications for yourself and your relatives. This step is mandated by UAE law (Federal Decree-Law No. 4 of 2016 on Medical Liability).
3. What is the turn‑around time for results?
Your CEBPA germline mutation results are reported within 3 to 4 weeks from sample collection. The laboratory completes sequencing, bioinformatics analysis, and clinical reporting in 21‑28 calendar days. A preliminary verbal update may be available after 2 weeks for urgent cases.
UAE Regulatory & Data Privacy Adherence
Your personal and genomic data are protected under Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All data handling complies with these frameworks. Our laboratory holds DHA Facility License No. 1143 and operates at Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE. We are ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139).
Clinical & Logistical Metadata
| Test Name | CEBPA Germline Mutation Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole blood (3–5 mL EDTA), extracted DNA (>1 µg), or dried blood spot (FTA card) |
| Methodology Used | Next‑Generation Sequencing (NGS) |
| ICD-10-CM Code | Z15.09 |
| LOINC Code | 41629-0 |
| DHA Facility License & Laboratory Address | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians